Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2022-07-11 Declaration of Voting R…
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the number of shares and voting rights as of June 30, 2022. This content directly relates to changes in share capital and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general regulatory filing (RNS). However, since it is a specific monthly disclosure about the total number of shares and voting rights, it is a direct report on capital structure changes, making SHA the most precise fit among the provided options, although it is not explicitly listed as a standard SEC form. Given the options, 'SHA' (Share Issue/Capital Change) covers changes in the number of shares comprising the capital. If SHA is interpreted strictly as new issues, then 'RNS' (Regulatory Filings) might be considered, but the content is highly specific to capital structure reporting. Comparing the definitions, SHA is the closest fit for reporting on the composition of the share capital and voting rights, which is a capital structure event, even if it's a routine monthly update. I will classify it as SHA based on the subject matter (capital composition/voting rights).
2022-07-11 French
Inside Information / News release on accounts, results
Earnings Release Classification · 100% confidence The document is an initial announcement of financial results for the fiscal year ending March 31, 2022. It highlights key financial metrics (income, operating expenses, cash position) and provides a summary of operational and R&D progress. It is not a full annual report (10-K) but rather a press release summarizing the results, which fits the definition of an Earnings Release (ER). FY 2022
2022-06-14 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 99% confidence The document is titled "MedinCell publie ses résultats financiers annuels consolidés" (MedinCell publishes its consolidated annual financial results) and covers the fiscal year "avril 2021 - mars 2022". It details key financial figures (Revenue, Operating Expenses, Cash Burn, Cash Position) and provides extensive operational updates on its product pipeline. This structure—a comprehensive review of the past fiscal year's financial performance and business activities—is characteristic of an Annual Report. Although the text is an announcement/summary, its content is the core of the annual financial disclosure, making '10-K' (Annual Report) the most appropriate classification for the underlying document type being summarized, rather than just an 'ER' (Earnings Release) or 'RPA' (Report Publication Announcement), given the depth and annual scope. Since the text explicitly states it is publishing the *annual consolidated financial results*, it represents the content of the 10-K. FY 2022
2022-06-14 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights), dated June 7, 2022, and references Article 223-16 of the AMF General Regulation. It explicitly provides a table detailing the number of shares and voting rights as of May 31, 2022. This content directly relates to changes in share capital and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general regulatory filing (RNS). However, since it specifically details the capital structure and voting rights count, SHA is the most precise fit among the defined categories, as it reports on the composition of the share capital.
2022-06-07 French
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is titled "Videoconference and release of fiscal 2021-2022 financial results on June 14, 2022" and announces a specific date and time for a video conference to present the "2021-2022 annual results". This structure—announcing the date and details of an upcoming earnings presentation—is characteristic of an Earnings Release (ER) or a precursor announcement. However, since it is specifically announcing the *release* of results and the associated conference call details, it functions as the initial communication of the period's financial performance highlights, fitting the definition of an Earnings Release (ER). It is not the full report (10-K) or the transcript (CT) itself, but the announcement leading up to the event where the results are discussed. Given the focus on announcing the results presentation date, ER is the most appropriate classification over RPA, which is usually for announcing the publication of a formal report document.
2022-06-07 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release dated June 7, 2022, announcing a webcast and presentation scheduled for June 14, 2022, to discuss the 'résultats annuels 2021-2022' (annual results for the fiscal year ending March 31, 2022). This announcement serves to inform investors about the upcoming release of financial results and the associated conference call. Since the document itself is an announcement about the release of results (and not the full financial report or the transcript of the call), it fits best as an Earnings Release (ER), which covers the initial announcement of periodical financial results (key highlights). Although it mentions the annual results, the primary function here is the announcement of the event where those results will be presented, which aligns closely with the ER definition, or potentially RPA if it were announcing the *publication* of a document, but here it announces a *videoconference* to present results. Given the context of announcing the presentation of annual results, ER is the most appropriate fit over RPA or CT. FY 2022
2022-06-07 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.